Therapy of Streptozotocin Induced Diabetes with a Bifunctional Antibody that Delivers Vinca Alkaloids to IL-2 Receptor Positive Cells

References

• Castano L., Eisenbarth G. Type 1 diabetes: A chronic autoimmune disease of human, mouse and rat. Ann. Rev. Immunol. 1990; 8: 647–679
   PubMed Web of Science ®Google Scholar
• Like A., Kislauskis E., Williams R., Rossini A. Neonatal thymectomy prevents spontaneous diabetes mellitus in the BB rat. Science 1982; 216: 644–646
   PubMed Web of Science ®Google Scholar
• Ogawa M., Maaruyama T., Hasegawa T., Kanaya T., Kobayashi F., Tochino Y., Uda H. The inhibitory effect of neonatal thymectomy on the incidence of insulitis in non-obese diabetes (NOD) mice. Biomedical Research 1985; 6: 103–105
   Google Scholar
• Bendelac A., Carnaud C., Bach J. Syngenic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4 + and Lyt-2 + T cells. J. Exp. Med. 1987; 166: 823–832
   PubMed Web of Science ®Google Scholar
• Kantwerk-Funke G., Burkart V., Kolb H. Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice. Clin. Exp. Immunol. 1991; 86: 266–270
   PubMed Web of Science ®Google Scholar
• Metroz-Dayer M., Mouland A., Brideau C., Duhamel D., Poussier P. Adoptive transfer of Diabetes in BB rats induced by CD4 T lymphocytes. Diabetes 1990; 39: 928–932
   PubMed Web of Science ®Google Scholar
• Jackson R. A., Morris M. A., Haynes B. F., Eisenbarth G. S. Increased circulating Ia-antigen-bearing T cells in Type I diabetes mellitus. N. Engl. J. Med. 1982; 306: 785
   PubMed Web of Science ®Google Scholar
• Koike T., Itoh Y., Ishii T., Ito I., Takabayashi K., Maruyama T., Tomioka H., Yoshida S. Preventative effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 1987; 36: 539–541
   PubMed Web of Science ®Google Scholar
• Herold K. C., Bluestone J. A., Montag A. G., Parihar A., Weigner A., Gress R. E., Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992; 41: 385–391
   PubMed Web of Science ®Google Scholar
• Vallera D. A., Carroll S. F., Brief S., Blazar B. R. Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse. Diabetes 1992; 41: 457–464
   PubMed Web of Science ®Google Scholar
• Sempe P., Bedossa P., Richard M., Villa M., Bach J., Boitard C. Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur. J. Immunol. 1991; 21: 1163–1169
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Minani Y. The IL-2/IL-2 receptor system: A current overview. Cell 1993; 73: 5–8
   PubMed Web of Science ®Google Scholar
• Waldmann T. A. The multichain interleukin 2 receptor: A target for immunotherapy in lymphoma autoimmune disorders, and organ allografts. Journal of the American Medical Association 1990; 263: 272–274
   PubMed Web of Science ®Google Scholar
• Pacheco-Silva A., Bastos M. G., Muggia R. A., Pankewycz O., Nichols J., Murphy J. R., Strom T. B., Rubin-Kelley V. E. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur. J. Immunol. 1992; 22: 697–702
   PubMed Web of Science ®Google Scholar
• Junghans R. P., Waldmann T. A., Landolfi N. R., Avdalovic N. M., Schneider W. P., Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990; 50: 1495–1502
   PubMed Web of Science ®Google Scholar
• Honsa S., Ichimori Y., Iwasa S. A human hybrid-hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by pseudomonas aeruginosa exotoxin A. Cytotechnology 1990; 4: 59
   PubMed Web of Science ®Google Scholar
• Stickney D. R., Slater J. B., Frincke J. M. Imaging and therapeutic potential of a bifunctional antibody in colon carcinoma. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1989; 29
   Google Scholar
• Pimm M. V., Robins R. A., Embleton M. J., Jacobs E., Markham A. J., Charleston A., Baldwin R. W. A bispecific monoclonal antibody against methotrexate and a human tumor associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Br. J. Cancer 1990; 61: 508–513
   PubMed Web of Science ®Google Scholar
• Corvalan J. R.F., Smith W., Gore V. A. Tumour therapy with vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognising both CEA and vinca alkaloids. Int. J. Cancer 1988; 2: 22–25
   Google Scholar
• Maclean J., Su Z., Guo Y., Sy M., Colvin R., Wong J. Anti-CD3: Anti-IL-2 Receptor Bispecific Monoclonal Antibody (Targeting of activated T cells in Vitro). J. Immunol. 1993; 150: 1619–1628
   PubMed Web of Science ®Google Scholar
• Haagen I. A., Van de Griend R., Clark M., Geerars A., Bast B., De Gast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19). Clin. Exp. Immunol. 1992; 90: 368–375
   PubMed Web of Science ®Google Scholar
• Takahashi H., Nakada T., Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993; 259: 1460–1463
   PubMed Web of Science ®Google Scholar
• Francois C., Boeffard F., Kaluza B., Weidle U. H., Jacques Y. Construction of a bispecific antibody reacting with the α-and β-chains of the human IL-2 receptor: High affinity cross-linking and high anti-proliferative efficiency. J. Immunol. 1993; 150: 4610–4619
   PubMed Web of Science ®Google Scholar
• Nistico P., Mortarini R., De Monte L. B., Mazzacchi A., Mariani M., Malavasi F., Parmiani G., Natali P. G., Anichini A. Cell retargeting by bispecific monoclonal antibodies: Evidence of bypass of intratumor susceptibility to cell lysis in human myelnoma. Journal of Clinical Investigation 1992; 90: 1093–1099
   PubMed Web of Science ®Google Scholar
• Kuus-Reichel K., Knott C. L., Sam-Fong P., Jue R., Corvalan J. R.F. Production and characterization of a bi-functional antibody (IVA039.1) with specificity for the mouse IL-2 receptor and vinca alkaloids. Hybridoma 1994; 13: 115–122
   PubMedGoogle Scholar
• Gillette R. W. Alternatives to pristane priming for ascitic fluid and monoclonal antibody production. J. Immunol. Methods. 1987; 99: 21–23
   PubMed Web of Science ®Google Scholar
• Ziegler M., Teneberg S., Witt S., Ziegler B., Hehmke B., Kohnert D., Egeberg J., Karlsson K., Lernmark A. Islet beta-cytotoxic monoclonal antibody against glycolipids in experimental diabetes induced by low dose streptozotocin and Freund's adjuvant. J. Immunol. 1988; 140: 4144–4150
   PubMed Web of Science ®Google Scholar
• Halpern S. E., Hagan P. L., Garver P. R., Koziol J. A., Chen A. W., Frincke J. M., Bartholomew R. J., David G. S., Adams G. H. Stability, characterization and kinetics of In-111-labeled monoclonal anti-tumor antibodies in normal animals and nude mouse-human tumor models. Cancer Res. 1983; 43: 5347–5355
   PubMed Web of Science ®Google Scholar
• Scatchard G. The attractions of proteins for small molecules and ions. Ann. NY. Acad. Sci. 1949; 51: 660–672
   Web of Science ®Google Scholar
• Corvalan J. R.F., Smith W., Gore V. A., Brandon D. R., Ryde P. J. Increased therapeutic effect of vinca alkaloids targeted to tumor by a hybrid-hybrid monoclonal antibody. Cancer Immunol. Immunother. 1987; 24: 138–143
   PubMed Web of Science ®Google Scholar
• Calabrese P., Parks R. Alkalating Agents, Antimetabolites, Hormones and Other Antiproliferative Agents. The Pharmacological Basis of Therapeutics, L. Goodman, A. Gilman. MacmillanePublishing, New York 1970; 1284–1287
   Google Scholar
• Kupiec-WEglinski J., Marianai G., Tanaka K., Di Stephano R., Stunkel K., Diamantstein T., Tilney N. Biodistribution of anti-interleukin 2 receptor monoclonal antibodies correlates with their therapeutic efficacy following transplantation. Cell. Immunol. 1989; 123: 148–157
   PubMed Web of Science ®Google Scholar
• Meyer D., Fineman M., Unger B., Frincke J. Kinetics of the dissociation of Indium-(p-substituted-benzyl) ethylenediaminetetraetic acid hapten analogues from the monoclonal anti-hapten antibody CHA255. Bioconjugate Chemistry 1990; 2: 278–284
   Google Scholar